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Abstract
Trials failed to demonstrate protective effects of investigational treatments on glomerular filtration rate (GFR) reduction in
Autosomal Dominant Polycystic Kidney Disease (ADPKD). To assess whether above findings were explained by unreliable
GFR estimates, in this academic study we compared GFR values centrally measured by iohexol plasma clearance with
corresponding values estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) and abbreviated
Modification of Diet in Renal Disease (aMDRD) formulas in ADPKD patients retrieved from four clinical trials run by a Clinical
Research Center and five Nephrology Units in Italy. Measured baseline GFRs and one-year GFR changes averaged 78.6626.7
and 8.4610.3 mL/min/1.73 m2 in 111 and 71 ADPKD patients, respectively. CKD-Epi significantly overestimated and aMDRD
underestimated baseline GFRs. Less than half estimates deviated by ,10% from measured values. One-year estimated GFR
changes did not detect measured changes. Both formulas underestimated GFR changes by 50%. Less than 9% of estimates
deviated ,10% from measured changes. Extent of deviations even exceeded that of measured one-year GFR changes. In
ADPKD, prediction formulas unreliably estimate actual GFR values and fail to detect their changes over time. Direct kidney
function measurements by appropriate techniques are needed to adequately evaluate treatment effects in clinics and
research.
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Introduction
Seven to ten percent of patients requiring chronic renal
replacement therapy because of end-stage renal disease (ESRD)
are affected by Autosomal Dominant Polycystic Kidney Disease
(ADPKD) [1–3]. Renal function loss in ADPKD is largely related
to the development and growth of cysts and concomitant disruption
of normal renal tissue [4]. Thus, experimental and clinical studies
tested drugs that specifically target factors - such as cyclic AMP and
mammalian Target of Rapamycin (mTOR) related pathways [5,6]
- that appear to be involved in the dysregulation of epithelial cell
growth, secretion, and matrix deposition that is characteristic of the
disease [7–11]. The enthusiasm on this line of research, however,
was stifled by the results of recent trials showing no appreciable
protective effect of sirolimus or everolimus therapy against
progressive glomerular filtration rate (GFR) decline in two large
cohorts of ADPKD patients [12,13]. In both trials the GFR was
estimated (eGFR) by using prediction formulas - the ‘‘Chronic
Kidney Disease Epidemiology Collaboration’’ (CKD-Epi) and the
‘‘abbreviated Modification of Diet in Renal Disease’’ (aMDRD)
equations – that are based on serum creatinine level, taken as an
endogenous marker of glomerular filtration [Levey A, et al. (2000) J
Am Soc Nephrol 11: 155A, Abstract] [14]. These formulas,
however, has been repeatedly challenged and there is increasing
evidence that their use might generate misleading information in
particular in subjects with normal or near normal kidney function
[15–19] [Porrini E et al. (2010) American Society of Nephrology,
Renal Week 2010, Denver, CO, November 16–21, Abstract F-
PO1244]. Thus, direct measurements of the GFR by gold-standard
techniques based on the use of exogenous markers of glomerular
filtration such as inulin, iohexol or radio-labeled tracers [20–24]
would be needed to adequately assess a treatment effect on GFR
decline in this population. To test this hypothesis we took
advantage from a cohort of ADPKD patients prospectively
monitored by serial GFR measurements and estimations in the
setting of controlled clinical trials coordinated by the Mario Negri
Institute for Pharmacological Research in Italy. In this population
we evaluated the relationships between GFR values centrally
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measured (mGFR) at inclusion and at one-year follow-up and the
concomitant GFR estimates obtained by prediction formulas
(eGFR). To this purpose the GFR was measured by using the
iohexol plasma clearance technique [21], a procedure previously
validated by comparative analyses with inulin renal clearance
showing that iohexol is a reliable marker of glomerular filtration in
normal subjects as well as in patients with different degree of renal
insufficiency [21]. Compared to renal inulin clearance this
procedure does not require urine collection or continuous infusion
of the filtration marker, and compared to 51Cr-EDTA and 99mTc-
DTPA plasma clearance techniques [25,26], it allows avoiding the
use of radiolabeled tracers. Both advantages facilitate kidney
function monitoring in everyday clinical practice and in research
[21,27–29]. Thus, the availability of direct GFR measurements
allowed to test the reliability of prediction formulas in patients with
ADPKD and to assess whether and to which extent their use can
affect the statistical power of a clinical trial aimed to detect the
protective effect of a given intervention on progressive renal
function loss in this population.
Methods
This was a fully academic, internally funded study with no
sponsor or company involvement in study design and data
recording, analysis, interpretation and reporting. All considered
trials conformed to the Declaration of Helsinki guidelines and
were approved by the ‘‘Comitato di Bioetica della Azienda
Ospedaliera Ospedali Riuniti di Bergamo’’. In addition, for the
ALADIN Study Ethics Committees of Lecce, Milan, Naples, and
Treviso approved the trial. All included patients provided written
consent to trial participation. Data were handled in respect of
patient anonymity and confidentiality.
Study population
We used measured and estimated GFR data obtained from
homogeneous cohorts of adult ADPKD subjects with baseline
eGFR .30 mL/min/1.73 m2 (by aMDRD equation) who had
been included in four studies designed, conducted, and monitored
by the Investigators of the Clinical Research Center for Rare
Diseases ‘‘Aldo e Cele Dacco`’’ of the Mario Negri Institute (Bergamo,
Italy). The ‘‘Safety and Efficacy of Long-acting Somatostatin
Treatment in Autosomal Dominant Polycystic Kidney Disease’’
study [30] and the ‘‘Sirolimus Treatment in Patients with
Autosomal Dominant Polycystic Kidney Disease’’ I (SIRENA I,
EUDRACT Nu: 2006-003427-37) [31] and II (SIRENA II,
EUDRACT Nu: 2007-005047-21) studies were run in cooperation
with the Nephrology Unit in Bergamo, whereas the ‘‘Effects of
Long-acting Somatostatin on Disease Progression in Patients with
Autosomal Dominant Polycystic Kidney Disease and Moderate to
Severe Renal Insufficiency Therapy’’ (ALADIN, EUDRACT Nu:
2005-005552-41) study involved also four Units in Lecce, Milan,
Naples, and Treviso, all in Italy. The first two studies evaluated the
short-term effects of six-month therapy with Sandostatin-LARH
Depot (Novartis Farma S.p.A., Origgio, Varese, Italy) or
RapamuneH (Wyeth-Lederle S.p.A., Aprilia, Latina, Italy) on
kidney volumes and function in the setting of a randomized, cross-
over design. The other two studies evaluated the long-term effect
of three-year treatment with the two agents on kidney volumes and
mGFR decline in the setting of a randomized, parallel-group
design. Baseline data were obtained from all studies (Somatostatin
study: 10, SIRENA I: 21, SIRENA II: 4, ALADIN: 76), whereas
one-year data were available only from the ALADIN study.
All studies excluded ADPKD patients with evidence of concom-
itant systemic, renal parenchymal (proteinuria $1 gr/24 hours) or
urinary tract disease, diabetes, cancer, psychiatric disorders, as well
as pregnant or lactating women or fertile women without effective
contraception. Considered variables were recorded according to
similar timetables in case record forms and databases which had a
similar frame. Thus, the homogeneity in patient characteristics,
study design and organization, monitored variables, and data
handling procedures allowed the merging of data in a common
meta-database and all considered outcomes could be analyzed with
a minimized risk of reasonably predictable biases.
GFR measurement and estimation
GFR was centrally determined at the laboratory of the Clinical
Research Center at patient inclusion and one year apart by using
the iohexol plasma clearance technique. GFR was determined by
the plasma clearance of iohexol. Briefly, on the morning of renal
function evaluation, 5 ml of iohexol solution (Omnipaque 300, GE
Healthcare, Milan, Italy) was injected intravenously over 2 minutes.
Blood samples were then taken at 120, 180, 240, 300, 360, 420, and
480 min for patients with expected mGFR#40 mL/min, and at
120, 150, 180, 210, and 240 min for those with expected
mGFR.40 mL/min. Blood iohexol plasma levels were measured
by high-performance-liquid chromatography. The clearance of
iohexol was calculated according to a one-compartment model
(CL1) by the formula: CL1=Dose/AUC, where AUC is the area
under the plasma concentration-time curve. According to Bro¨ch-
ner-Mortensen [32], plasma clearances were then corrected by
using the formula CL= (0.9907786CL1)2(0.0012186CL1
2). GFR
values were then normalized to 1.73 m2 of body surface area (BSA).
The procedure has remarkable precision over a wide range of
kidney function [33] as documented by the low mean intra-
individual coefficient of variation (5.59%) and good reproducibility
index (6.28%) observed in repeated measurements in subjects with
near-terminal kidney failure, normal GFR or even hyperfiltration.
The morning of each iohexol clearance study, serum creatinine
concentration was measured with the modified rate Jaffe´ method
using an automatic device (Beckman Synchron LX20 Pro, Beckman
Coulter S.p.A., Cassina De’ Pecchi, Italy) and demographic and
anthropometric data considered in CKD-Epi and aMDRD
equations [Levey A, et al. (2000) J Am Soc Nephrol 11: 155A,
Abstract] [14] were recorded. For CKD-Epi estimates, measured
serum creatinine values were standardized to the isotope-dilution-
mass-spectrometry method by the equation provided by Beckman-
Coulter. GFR values estimated by both models were normalized.
Statistical analysis
Data were expressed as mean 6 standard deviation (SD) or
median. The relationships between measured and estimated GFR
values at baseline, as well as between one-year changes in
measured and estimated GFRs, were studied by regression
analyses considering Pearson correlation coefficient and Lin
concordance correlation coefficient as an index to evaluate the
degree to which pairs of observations fall on the 45u line through
the origin [34]. Additional sensitivity analyses were performed by
using the Deming regression. Analyses were performed in the
study group as a whole and in two subgroups with baseline
mGFR$ or ,70 mL/min/1.73 m2 considered separately.
Bias, mean percent error (MPE) and mean percent absolute
error (MAPE) were determined as previously described [35].
Scatter was defined as the median absolute difference between
measured and estimated GFR. Taking into account that the
reproducibility of the iohexol plasma clearance is 6.28% [33], the
eGFR values lying within the 610% error range were a priori
considered as virtually identical to mGFR values. The trend of the
errors was represented by Bland-Altman analysis: the differences
GFR Estimation in ADPKD
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between estimated and measured GFRs (or estimated and
measured one-year GFR differences) were plotted versus the
mean of estimated and measured GFRs (or estimated and
measured one-year GFR differences). Data were compared by
paired or unpaired t-test, Mann-Whitney test, chi-square test or
one way analysis of variance (ANOVA), as appropriate. The
statistical significance level was defined as p,0.05. All analyses
were performed by MedCalc (11.3.3 version) or MS Excel.
Results
Patient characteristics
Baseline data were available from 111 patients. They were
relatively young and predominantly male subjects (Table 1).
Thirty-three patients were overweight and 13 obese (according to
a body mass index between 25 and 30 kg/m2 or exceeding 30 kg/
m2, respectively). Serum creatinine exceeded the upper limit of the
normal range (1.30 mg/dL) in 39 cases. The GFR was less than
the lower limit of the normal range (80–120 mL/min/1.73 m2) in
62 cases. Only six patients were hyperfiltering (mGFR.120 mL/
min/1.73 m2). No patient was on concomitant treatment with
drugs known to interfere with creatinine tubular handling.
Relationships between measured and estimated GFR at
baseline
The GFRs estimated by CKD-Epi and aMDRD formulas were
significantly correlated (p,0.001) with measured GFRs (Figure 1,
Left and Right Panel, respectively). The ‘‘r’’ correlation (0.908 vs.
0.891) and Lin concordance (0.899 vs. 0.872) coefficient were
slightly higher with CKD-Epi than aMDRD estimates. Similar
results were obtained by using the Deming regression model.
Analyses indicated a proportional difference (slope statistically
different from 1) and a constant negative difference (intercept
significantly different from 0) for the CKD-Epi and aMDRD
formulas respectively. CKD-Epi significantly overestimated and
aMDRD underestimated mGFR values, respectively (Table 2).
Mean percent errors vs. actual values showed similar trends,
whereas mean absolute percent errors were similar with the two
estimates (Table 2). Overall, less than half of the estimates deviated
by ,10% from actual values. The accuracy was poor for both
estimates, although the percentage of acceptable estimates was
slightly higher with CKD-Epi than aMDRD. With both formulas,
scatter and mean absolute differences between measured and
estimated GFR changes ranged between 7 and 11 mL/min/
1.73 m2. On the basis of the results of Bland-Altman analyses, the
performance of the two equations was similarly poor at any degree
of renal function, with a trend to greater errors for higher levels of
mGFR (Figure 2). The differences between the upper and lower
limits of agreement were 48.3 mL/min/1.73 m2 and 50.1 mL/
min/1.73 m2 for the CKD-Epi and the aMDRD formula,
respectively. However, the mean bias was negligible since it
reflects the mean of over- and underestimation of individual
mGFR values. The absolute differences between measured and
estimated GFR values significantly increased (CKD-Epi: p,0.01,
Table 1. Patients characteristics at inclusion.
Whole study group Patients with baseline and one-year data Patients with baseline data only
n 111 71 40
Age (yr) 38.2067.87 37.1567.98 40.0667.40
Male sex – no. (%) 62(55.86) 34(47.89) 28(70.00)
Height (cm) 171.1269.50 170.0169.85 173.0868.62
Weight (Kg) 73.28614.65 72.49614.58 74.68614.86
Body Mass Index (kg/m2){ 24.9163.86 24.9663.91 24.8163.83
Body Surface Area (m2)$ 1.8560.21 1.8360.21 1.8860.21
Systolic Blood Pressure (mmHg) 130.21615.50 127.74615.49 136.06614.08‘
Diastolic Blood Pressure (mmHg) 84.91611.22 84.07612.22 86.8968.25
Serum creatinine (mg/dL)# 1.2160.46 1.1260.45 1.3760.46‘*
Uric Acid (mg/dL) 5.4161.61 5.1861.63 5.8361.50‘
GOT/AST (U/L) 19.9966.36 19.6167.24 20.6964.33
GPT/ALT (U/L) 20.09611.07 19.48612.39 21.2168.17
Proteinuria (g/24 h) 0.2560.52 0.2860.62 0.1660.13
Albuminuria (mg/min) 52.86665.02 61.89679.63 40.81635.36
GFR (mL/min/1.73 m2) 78.56626.70 83.13627.52 70.45623.38‘
Antihypertensive therapy - no. (%) 73 (65.77) 44 (61.97) 29 (72.50)
ACEi – no. (%) 55 (49.55) 33 (46.48) 23 (57.50)
CCB – no. (%) 12 (10.81) 8 (11.27) 4 (10.00)
ARBs – no. (%) 23 (20.72) 16 (22.54) 7 (17.50)
Antihypertensive drugs - no. 2 (1–3) 2 (1–3) 1 (1–2)
Data are mean6SD.
{The body mass index is the weight in kilograms divided by the square of the height in meters.
$The body surface area is calculated with the Dubois&Dubois formula.
#To convert values for serum creatinine to micromoles per liter, multiply by 88.4.
*p,0.05 vs. whole study group;
‘p,0.05 vs. patients with baseline and one-year data.
doi:10.1371/journal.pone.0032533.t001
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Figure 1. Correlation between estimated and measured by iohexol plasma clearance GFR. Values estimated by CKD-Epi and aMDRD
formulas are shown in the left and right panel respectively. Dot lines are identity lines; continuous lines are regression lines.
doi:10.1371/journal.pone.0032533.g001
Table 2. Performance of CKD-Epi and aMDRD equations in predicting GFR at inclusion in 111 ADPKD patients as a whole and
ranked according to mGFR,70 (n = 45) and $70 (n = 66) mL/min/1.73 m2.
Overall mGFR,70 mGFR$70
CKD-Epi Estimated GFR 81.37629.39‘ 52.85612.58 100.82620.18‘
Bias 2.81612.32 0.8567.99 4.15614.46
Mean % Error 3.84615.74 2.15614.91 4.98616.30
Mean Absolute % Error 12.50610.24 11.9469.01 12.88611.06
Scatter 7.01 4.69 9.88
Mean Absolute Differences 9.5868.20 6.2664.96 11.8469.18
Estimates within 10% 51.35 51.11 51.52
Pearson Coefficient 0.908 0.775 0.715
Lin Coefficient 0.899 0.760 0.692
aMDRD Estimated GFR 73.01627.95* 47.82610.39* 90.18622.59u
Bias 25.55612.79 24.1767.08 26.49615.51
Mean % Error 26.93614.69 27.23613.01 26.72615.82
Mean Absolute % Error 13.3269.23 11.7669.01 14.3869.29
Scatter 8.92 4.60 11.24
Mean Absolute Differences 10.7668.82 6.3465.18 13.7769.53
Estimates within 10% 41.44 51.11 34.85
Pearson Coefficient 0.891 0.770 0.729
Lin Coefficient 0.872 0.712 0.672
Iohexol plasma clearance: overall: 78.56626.70 mL/min/1.73 m2; GFR,70: 51.99610.49 mL/min/1.73 m2; GFR$70: 96.67617.63 mL/min/1.73 m2.
Data are mean6SD or median.
Estimated GFR, Bias, Scatter and Mean Absolute Differences are in mL/min/1.73 m2.
*p,0.001;
up,0.01;
‘p,0.05 vs. iohexol plasma clearance.
doi:10.1371/journal.pone.0032533.t002
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r = 0.248; aMDRD: p,0.001, r = 0.462) for increasing levels of
baseline mGFR (Figure 3). Analyses considering separately
subjects with mGFR at inclusion , or $70 mL/min/1.73 m2
(Figure 4) showed that the accuracy of both prediction formulas
was poor in either group (Table 2).
Relationships between measured and estimated GFR
changes at one year vs. baseline
Measured and estimated one-year GFR data were available in
71 of the 111 included patients. Demography, clinical and
laboratory characteristics at inclusion of patients with or without
one-year outcome data were similar, with the exception of mGFR
and serum creatinine levels (Table 1). Consistently with data in the
whole study group, baseline mGFR values were significantly
overestimated and underestimated by CKD-Epi and aMDRD
formulas, respectively. At one year the difference between
estimated and measured GFRs was still significant only when
CKD-Epi estimates were considered (Table 3).
Overall, at one-year, mGFR decreased by 8.4 mL/min/1.73 m2
vs. baseline, a reduction that CKD-Epi and aMDRD significantly
underestimated by 59% and 53%, respectively (Table 3). Bias, mean
percent errors and mean absolute percent errors of estimated vs.
measured one-year GFR changes were similar with the two
equations (Table S1). Only 8.57% and 5.71% of the CKD-Epi
and aMDRD estimates deviated by less than 10% from actual
values, respectively. The accuracy was poor for both estimates,
although the percentage of acceptable estimates was slightly higher
with the CKD-Epi than with the aMDRD formula. With both
formulas, scatter and mean absolute differences between measured
and estimated GFR changes approximated 10 mL/min/1.73 m2
(Table S1), a value that exceeded the 8.4 mL/min/1.73 m2 GFR
change actually measured at one year (Table 3). No significant
Figure 2. Agreement between measured and estimated GFR values. Bland-Altman plot of the difference between GFR estimated (eGFR) by
the CKD-Epi (Upper panel) and by aMDRD (Lower panel) formulas and measured GFR (mGFR) vs. the mean of the two determinations. Straight line
and dashed lines indicate mean difference and 95% limits of agreement, respectively.
doi:10.1371/journal.pone.0032533.g002
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correlation was found between mGFR changes and changes
estimated either by the CKD-Epi and the aMDRD formula
(Figure 5). At Bland-Altman analyses, the performance of the two
equations was similarly poor at any level of renal function changes
(Figure 6). The differences between the upper and lower limits of
agreement were 48.3 mL/min/1.73 m2 and 49.8 mL/min/
1.73 m2 for the CKD-Epi and the aMDRD formula, respectively.
The absolute differences between measured and estimated GFR
changes significantly increased (CKD-Epi: p= 0.020 r= 0.275;
aMDRD: p=0.004, r = 0.335) for increasing levels of baseline
mGFR (Figure 7). Actually, the analysis of the subgroups of subjects
with mGFR at inclusion , or $70 mL/min/1.73 m2 showed that
the accuracy in assessing GFR change by both CKD-Epi and
aMDRD formulas was poorer for mGFR higher than 70 mL/min/
1.73 m2 (Table 3). Nevertheless, as shown in Figure 8, even in
subjects with mGFR,70 mL/min/1.73 m2 the extent of GFR
changes predicted by both formulas was fully independent of
actually measured changes. Consistently, in this subgroup of
subjects estimates of one-year GFR changes based on CKD-Epi
and aMDRD equations deviated with large percent errors from
actual changes measured by iohexol plasma clearance (Table S1).
Discussion
The key findings of our present analysis in a relatively large
cohort of adult ADPKD patients who had their GFR values
Figure 3. Absolute differences between measured and estimated GFR values vs baseline measured GFR. The absolute differences
significantly increase for both CKD-Epi (Upper panel) and aMDRD (Lower panel) formulas for increasing values of GFR. Continuous lines are regression lines.
doi:10.1371/journal.pone.0032533.g003
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centrally measured by a gold standard procedure such as the
iohexol plasma clearance technique [21] and at the same time
estimated by the CKD-Epi and aMDRD prediction formulas, can
be summarized in the following 3 points:
i. GFR values estimated by the two formulas significantly
correlated with measured GFRs. Data, however, were biased
by a significant overestimation with the CKD-Epi and
underestimation with the aMDRD formula. Moreover, there
was a wide and unpredictable deviation of estimated data from
measured values, with less than 50 percent of GFR values being
predicted with an adequate accuracy by the two equations.
ii. One-year GFR changes estimated by both prediction
formulas failed to correlate to any appreciable extent with
measured changes. Moreover, data were biased by a
systematic underestimation of measured GFR changes that
averaged 50 percent with both formulas. Again, there was a
wide and unpredictable deviation of estimated from mea-
sured GFR changes, with less than nine percent of GFR
changes being reliably predicted by the two equations. Of
note, deviations of estimated data even exceeded the actually
measured GFR changes.
iii. Because of imprecise estimation of actual GFR values and
unreliable prediction of GFR changes over time, both CKD-
Epi and aMDRD equations fail to provide useful information
in the setting of clinical trials aimed to test the effect of
experimental treatments on progressive renal function loss in
patients with ADPKD.
In a previous prospective analysis of ADPKD patients with
baseline GFR.70 mL/min/1.73 m2, GFR slopes calculated on
the basis of serial GFR measurements by iothalamate clearance
better correlated with a series of baseline predictors of disease
progression than GFR slopes calculated by using aMDRD and
Cockcroft-Gault GFR estimates [36]. The above findings can be
explained by the bias in calculating GFR slopes using creatinine-
based prediction equations. Actually, other Authors have suggest-
ed that in early stages of CKD the variability in serum creatinine
levels might reflect creatinine production related to muscle mass or
protein intake more than glomerular filtration [36].
Figure 4. Relationship between GFR values ranked according to renal function. Correlation between GFR measured by iohexol plasma
clearance and GFR estimated by the CKD-Epi (Upper panels) and aMDRD (Lower panels) formulas in patients with baseline GFR, or $70 mL/min/
1.73 m2 considered separately (Left and Right panels, respectively). Dot lines are identity lines; continuous lines are regression lines.
doi:10.1371/journal.pone.0032533.g004
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Our present data confirm that prediction formulas, including the
CKD-Epi equation - not considered in previous studies - are far from
accurate in estimating GFR and are fully unreliable in estimating
GFR changes in subjects with ADPKD, and provide formal
evidence that this limitation is independent of kidney function and
applies also to individuals with more severe renal insufficiency. This
is in harmony with cross-sectional data by Orskov and colleagues
[37] showing that the performance of prediction formulas, including
CKD-Epi and aMDRD in estimating renal function, was poor
across a wide range of GFRs fromCKD stage 1 to 5. Here we extend
these data by providing the fully novel evidence that the CKD-Epi
and aMDRD formulas do not allow any useful information to
predict GFR changes over time, a limitation that, again, applies also
to subjects with lower GFRs to start with. These findings are in line
with previous observations in other population, such as in kidney
transplant recipients, showing that predictive performance of GFR
equations, including aMDRD and Cockcroft-Gault formulas, in
detecting renal function changes over time was remarkably inferior
to that of GFR measurements with iohexol plasma clearance [35].
On the other hand, the wide variability of GFR estimates we
observed in our ADPKD patients might be explained by changes in
tubular creatinine handling that could be specific to the disease.
Creatinine accumulating into non-communicating cysts, in partic-
ular in those originating from proximal tubuli, cannot be excreted
into urine [1] and might back-diffuse into the circulation. We
speculate that this would induce serum creatinine changes that are
independent of glomerular filtration and that might bias any GFR
estimation based on serum creatinine levels.
As demonstrated in our present analyses, both underestimation
and dispersion of data synergistically converge to decrease the
power of statistical analyses aimed to demonstrate a treatment
effect on GFR. In this perspective, failure to detect any, even
marginal, correlation between measured and estimated GFR
changes over one year follow-up, definitely challenged the
reliability of any clinical trial using CKD-Epi and aMDRD
equations to test the effects of experimental treatments in ADPKD
[12,13]. Similar considerations apply to the several prediction
formulas developed over the last 40 years for GFR estimation that
are flawed (even to a larger extent) by the same limitations
described for the above equations.
In another perspective, an encouraging implication of the above
findings is that the results of studies based on the use of prediction
formulas cannot be taken to definitely discard the idea that mTOR
inhibitors may be suitable for the treatment of ADPKD [6].
Table 3. Measured and estimated one-year GFR changes vs.
baseline in 71 ADPKD patients as a whole and ranked
according to mGFR,70 (n = 25) and $70 (n = 46) mL/min/
1.73 m2.
Overall mGFR,70 mGFR$70
Iohexol Baseline GFR 83.13627.52 52.64610.28 99.69618.03
One-Year GFR 74.70627.83 45.5269.77 90.56620.58
GFR Change 28.43610.31 27.1367.51 29.13611.57
CKD-Epi Baseline GFR 86.84629.56‘ 54.10612.05 104.63618.31‘
One-Year GFR 81.84632.41* 47.00614.40 100.78621.96*
GFR Change 24.9968.96‘ 27.1066.29 23.85610.00u
aMDRD Baseline GFR 77.94628.54u 48.7469.70‘ 93.81622.04‘
One-Year GFR 73.41629.97 42.74611.68 90.08622.75
GFR Change 24.5369.73‘ 26.0065.46 23.72611.39‘
Data are in mL/min/1.73 m2; mean6SD.
*p,0.001;
up,0.01;
‘p,0.05 vs. iohexol plasma clearance.
doi:10.1371/journal.pone.0032533.t003
Figure 5. Relationship between measured and estimated 1-year GFR changes. Correlation between measured 1-year GFR changes vs.
baseline and corresponding changes estimated by CKD-Epi (Left panel) and aMDRD (Right panel) formulas. Dot lines are identity lines; continuous
lines are regression lines.
doi:10.1371/journal.pone.0032533.g005
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Limitations and Strengths
The major limitation of our study was the post-hoc nature of an
observational analysis of subjects included in trials originally
designed for other purposes. Moreover, since longitudinal data
were available only for a subgroup, GFR changes over time could
be analyzed in a relatively small number of patients. Finally, the
availability of only two sequential GFR measurements per patient
did not allow comparative analyses between slopes of measured
and estimated GFRs. Thus, our present findings can be considered
as hypothesis generating and merit confirmation in ad hoc studies
formally comparing GFR changes over time directly measured by
gold standard procedures and indirectly estimated by using
prediction formulas. A major strength was that all patients were
monitored according to predefined and standardized guidelines
and by using a standard procedure for GFR measurement largely
applied to monitor renoprotective effects of given treatments on
renal function in patients with CKD participating to clinical trials
[38–42]. Iohexol plasma clearance also showed a good agreement
with inulin renal clearance (the gold standard for renal function
assessment) in subjects with different degree of renal function
[21,28,29]. Consistently, GFR decline measured in our study
patients was quite similar to that previously reported after the
fourth decade of age in ADPKD patients prospectively monitored
by serial GFR measurements by using the iothalamate plasma
clearance technique [43].
Moreover, finding that no patients was on concomitant
treatments known to affect creatinine tubular handling, avoided
the confounding effect of GFR-independent changes in serum
creatinine levels that might have further reduced the reliability of
prediction formulas that use serum creatinine as an endogenous
marker of glomerular filtration. Our present data also had a large
external validity since selection criteria allowed identifying a study
population which is representative of the average population of
ADPKD patients who refer to a Nephrology Unit in every day
Figure 6. Bland-Altman plots of measured and estimated 1-year changes. Graphs show the agreement between estimated by CKD-Epi
(Upper panel) or by aMDRD (Lower panel) formulas and corresponding measured 1-year GFR changes vs. baseline. Straight line and dashed lines
indicate mean difference and 95% limits of agreement, respectively.
doi:10.1371/journal.pone.0032533.g006
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clinical practice. Moreover, GFR estimates were based on serum
creatinine levels measured in laboratories of different centers by
using validated local procedures, which faithfully reflects how
prediction formulas are routinely used in real life.
Conclusions
In our present series of patients with ADPKD, independent of
their kidney function, prediction formulas, including those that
have been most recently implemented to improve the performance
in GFR estimation [14] unreliably estimated actual GFR values
and failed to detect their changes over time. Study findings suggest
that these surrogate outcome variables are not appropriate to
assess progression of ADPKD and response to treatment in
research and clinics. Long-term, adequately powered clinical trials
with direct measurement of kidney function by appropriate
techniques may help better evaluating the efficacy of therapeutic
strategies in this clinical setting, as well as in other chronic kidney
diseases.
Supporting Information
Table S1 Performance of CKD-Epi and aMDRD equations in
predicting one-year GFR changes vs. baseline in 71 ADPKD
Figure 7. Absolute differences between measured and estimated 1-year GFR changes vs baseline measured GFR. The absolute
differences between 1-year GFR changes for both CKD-Epi (Upper panel) and aMDRD (Lower panel) formulas significantly increase for increasing
values of GFR. Continuous lines are regression lines.
doi:10.1371/journal.pone.0032533.g007
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patients as a whole and ranked according to mGFR,70 (n= 25)
and $70 (n= 46) mL/min/1.73 m2.
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